Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

  • Norbert Müller
  • Monika Empl
  • Michael Riedel
  • Markus Schwarz
  • Manfred Ackenheil
Original Paper


The cytokines interleukin-2 (IL-2) and interleukin-6 (IL-6) increase during immune activation, they are released from activated astrocytes and microglial cells in the central nervous system (CNS), and they are able to enhance the catecholaminergic neurotransmission. This study focused on the soluble receptors of IL-2 and IL-6 (sIL-2R, sIL-6R) as a part of the regulation system of IL-2 and IL-6. We studied serum levels of sIL-2R in 30 schizophrenic patients not under neuroleptic medication during an acute exacerbation of the disease and reexamined these patients under neuroleptic treatment after clinical improvement. The SIL-6R levels of 39 schizophrenic patients were estimated under the same conditions. The results were compared with the levels of sIL-2R and sIL-6R in 42 healthy controls. No difference was found between the schizophrenic patients before neuroleptic treatment and the healthy controls. During neuroleptic treatment, however, there was a significant increase of sIL-2R levels and a significant decrease of the sIL-6R levels between the pre- and post-conditions. In comparison with healthy controls, the treatment group also showed increased sIL-2R levels and decreased sIL-6R levels. These results suggest that treatment with neuroleptics is associated with increased sIL-2R and decreased sIL-6R. Since sIL-2R bind and inactivate IL-2, whereas sIL-6R form an active complex with IL-6, the increase of sIL-2R and the decrease of sIL-6R together may reflect a functional down regulation of these activating cytokines. This suggests that neuroleptic therapy has a differentiated immunomodulatory effect.

Key words

sIL-6R sIL-2R Immunology Schizophrenia Neuroleptics 


  1. American Psychiatric Association (1990) Structured clinical interview for DSM-III-R. American Psychiatric Press, Washington DCGoogle Scholar
  2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R), 3rd edn, revised. American Psychiatric Press, Washington DCGoogle Scholar
  3. Baker GA, Syntalo R, Blumenstein J (1977) Effects of psychotropic agents upon the blastogenic response on human T-lymphocytes. Biol Psychiatry 12: 159–169PubMedGoogle Scholar
  4. Banks WA, Kastin AJ (1992) The interleukins-1 alpha, -1 beta, and -2 do not acutely disrupt the murine blood-brain barrier. Int J Immunopharmacol 14: 629–636PubMedCrossRefGoogle Scholar
  5. Barral-Netto M, Barrai A, Santos SB, Carvalho EM, Badaro R, Rocha H, Reed SG, Johnson WD Jr (1991) Soluble IL-2 receptors as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol 147: 281–284PubMedGoogle Scholar
  6. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A (1995) Cytokine production in drug-free and neuroleptictreated schizophrenic patients. Biol Psychiatry 38: 297–302PubMedCrossRefGoogle Scholar
  7. Brivio S, Lissoni P, Mancini D, Tisi E, Tancini G, Barni S, Nociti V (1991) Effect of antitumor surgery on soluble interleukin-2 receptor serum levels. Am J Surg 161: 466–469PubMedCrossRefGoogle Scholar
  8. Damle RN, Advani SH, Gangal SG (1992) Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin’s disease. Int J Cancer 50: 192–196PubMedCrossRefGoogle Scholar
  9. Denicoff KD, Rubinoff DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA (1987) The neuropsychiatric effects of treatment with Interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107: 293–300PubMedGoogle Scholar
  10. Gallien M, Schnetzler JP, Morin J (1977) Antinuclear antibodies and lupus cells in 600 hospitalized phenothiazine treated patients. Ann Med Psychol Med 1: 237–248Google Scholar
  11. Ganguli R, Rabin BS (1989) Increased serum Interleukin 2 receptor levels in schizophrenic and brain damaged subjects. Arch Gen Psychiatry 46: 292PubMedGoogle Scholar
  12. Ganguli R, Yang Z, Shurin G, Chengappa R, Brar JS, Gubbi AV, Rabin BS (1994) Serum Interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51: 1–10PubMedCrossRefGoogle Scholar
  13. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, Rabin B (1995a) Mitogen-stimulated interleukin 2 production in never-medicated, first episode schizophrenics: the influence of age of onset and negative symptoms. Arch Gen Psychiatry 52: 878Google Scholar
  14. Ganguli R, Brar JS, Rabin BS (1995b) Reply on: Pollmächer T et al. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch Gen Psychiatry 52: 668–672PubMedGoogle Scholar
  15. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H (1991) Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 40: 445–452PubMedCrossRefGoogle Scholar
  16. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H (1995) Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 15: 237–242PubMedCrossRefGoogle Scholar
  17. Hornung N, Raskova J, Raska K, Degiannis D (1992) I1-2 responsiveness of lectin-induced lymphoblasts: soluble IL-2 receptor release and differential in vitro effects of immunosuppressants. Int J Immunopharmacol 14: 753–760PubMedCrossRefGoogle Scholar
  18. Kay SR, Oppler LA, Fiszbein A (1986) Positive and negative syndrome scale (PANSS) manual. Multi-Health Systems, North Tonawanda, New YorkGoogle Scholar
  19. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated levels of Interleukin-2 in neuroleptic-free schizophrenics. Am J Psychiatry 150: 1408–1410PubMedGoogle Scholar
  20. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 49: 2021–2027Google Scholar
  21. Maes M, Meltzer HY, Bosnians E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89: 346–351PubMedCrossRefGoogle Scholar
  22. Maes M, Bosnians E, Ranjan R, Vandoolaeghe B, Meltzer HY, Ley M de, Berghmans R, Stans G, Desnyder R (1996) Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 21: 39–50PubMedCrossRefGoogle Scholar
  23. McAllister CG, Rapaport MH, Pickar D, Paul SM (1989) Effect of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. Arch Gen Psychiatry 46: 956–957PubMedGoogle Scholar
  24. McAllister CG, van Kämmen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152: 1291–1297PubMedGoogle Scholar
  25. Müller N, Ackenheil M (1995) Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: the relationship to negative symptomatology. Schizophr Res 14: 223–228PubMedCrossRefGoogle Scholar
  26. Müller N (1997) The role of the cytokine network in the CNS and psychic disorders. Nervenarzt 68: 11–20PubMedCrossRefGoogle Scholar
  27. Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R (1991) Cellular immunity in schizophrenic patients before and during neuroleptic therapy. Psychiatry Res 37: 147–160PubMedCrossRefGoogle Scholar
  28. Müller N, Empel M, Putz A, Schwarz M, Ackenheil M (1997a) Immunological effects of treatment in schizophrenia. In: Henneberg AE, Kaschka WP (eds) Immunological alterations in psychiatric diseases. Karger, Basel, pp 78–84CrossRefGoogle Scholar
  29. Müller N, Dobmeier P, Empel M, Riedel M, Schwarz M, Ackenheil M (1997b) Soluble IL-6 Receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur Psychiatry 12: 294–299CrossRefPubMedGoogle Scholar
  30. Müller N, Hadjamu M, Riedel M, Primbs J, Ackenheil M, Gruber R (submitted) The adhesion-molecule receptor expression on T helper cells increases during treatment with neuroleptics and is related to the blood-brain barrier permeability in schizophrenia. Am J PsychiatryGoogle Scholar
  31. Norris JG, Benveniste EN (1993) Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 45: 137–146PubMedCrossRefGoogle Scholar
  32. Plata-Salaman CR (1991) Immunoregulators in the nervous system. Neurosci Behav Rev 15: 185–215Google Scholar
  33. Plata-Salaman CR, Ffrench-Mullen JM (1993) Interleukin-2 modulates calcium currents in dissociated hippocampal CA1 neurons. Neuroreport 4: 579–581PubMedCrossRefGoogle Scholar
  34. Pollmächer T, Hinze-Selch D, Mullington J, Holsboer F (1995) Clozapine-induced increase in plasma levels of soluble Interleukin-2 receptors. Arch Gen Psychiatry 52: 877–878PubMedGoogle Scholar
  35. Ransohoff RM, Benveniste EN (1996) Cytokines and the CNS. CNC Press NY, LondonGoogle Scholar
  36. Rapaport MH, McAllister CG, Pickar D, Nelson DM, Paul SM (1989) Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch Gen Psychiatry 46: 292Google Scholar
  37. Rapaport MH, McAllister CG, Kirch DG, Pickar D (1990) The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol Psychiatry 29: 715–717CrossRefGoogle Scholar
  38. Rapaport MH, Doran AR, Nelson DM, McAllister CG, Magliozzi JR, Paul SM (1991) Haloperidol and soluble Interleukin-2 receptors. Biol Psychiatry 30: 1063–1065PubMedCrossRefGoogle Scholar
  39. Rapaport MH, Torrey EF, McAllister CG, Nelson DM, Pickar D, Paul SM (1993) Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci 243: 7–10PubMedCrossRefGoogle Scholar
  40. Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DM, Kirch DG, Paul SM (1994) Increased soluble Interleukin-2 receptors in Caucasian and korean schizophrenic patients. Biol Psychiatry 35: 767–771PubMedCrossRefGoogle Scholar
  41. Reiber H, Felgenhauer K (1987) Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chem Acta 163: 319–328CrossRefGoogle Scholar
  42. Russo R, Ciminale M, Ditommaso S, Siliquini R, Zotti C, Ruggenini AM (1994) Hepatitis B vaccination in psychiatric patients. Lancet I 343: 394CrossRefGoogle Scholar
  43. Saunders JC, Muchmore E (1964) Phenothiazine effect on human antibody synthesis. Br J Psychiatry 110: 84–89PubMedCrossRefGoogle Scholar
  44. Sawada M, Suzumura A, Marunouchi T (1992) TNF-alpha induces IL-6 production by astrocytes, but not by microglia. Brain Res 583: 296–299PubMedGoogle Scholar
  45. Schleuning MJ, Duggan A, Reem GH (1989) Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes. Eur J Immunol 19: 1491–1496PubMedCrossRefGoogle Scholar
  46. Schleuning M, Brumme V, Wilmanns W (1994) Inhibition of cyclosporin A/FK 506 resistant, lymphokine-induced T-cell activation by phenothiazine derivates. Naunyn-Schmiedeberg’s Arch Pharmacol 350: 100–103CrossRefGoogle Scholar
  47. Schöbitz B, Pezeshki G, Pohl T, Hermann U, Heinrich PC, Holsboer F, Reul JM (1995) Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 9: 659–664PubMedGoogle Scholar
  48. Smith RS (1991) Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes? Med Hypotheses 34: 225–229PubMedCrossRefGoogle Scholar
  49. Smith RS (1992) A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 39: 248–257PubMedCrossRefGoogle Scholar
  50. Tibbling G, Link H, Ohmann S (1977) Principles of albumin and IgG analyses in neurological disorders. I: Establishment of reference values. Scand J Clin Lab Invest 37: 385–390PubMedCrossRefGoogle Scholar
  51. Villemain F, Chatenoud L, Galinowski A, Homo-Delarche F, Genestet D, Loo H, Zarifarain E, Bach JF (1989) Aberrant T-cellmediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 146: 609–616PubMedGoogle Scholar
  52. Waguespack PJ, Banks WA, Kastin AJ (1994) Interleukin-2 does not cross the blood-brain barrier by a saturable transport system. Brain Res Bull 34: 103–109PubMedCrossRefGoogle Scholar
  53. Wilke I, Arolt V, Rothermundt M, Weitzsch Ch, Hornberg M, Kirchner H (1996) Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246: 279–284PubMedCrossRefGoogle Scholar
  54. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643: 40–49PubMedCrossRefGoogle Scholar
  55. Zarrabi MH, Zucker S, Miller F, Derman RM, Romeno GS, Hartnett JA, Varma AO (1979) Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Int Med 91: 194–199PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Norbert Müller
    • 1
  • Monika Empl
    • 1
  • Michael Riedel
    • 1
  • Markus Schwarz
    • 1
  • Manfred Ackenheil
    • 1
  1. 1.Psychiatric HospitalLudwig Maximilian UniversityMunichGermany

Personalised recommendations